AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23999980 — intervention group
Group type: COMPARATOR
Intervention: Primary care management only (consultation with a general practitioner followed by information and advice on exercises)
Number of subjects: 241
Study 21529831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile device balance game for 10 minutes
Number of subjects: 40
Study 21529831 — intervention group
Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 40
Study 18178111 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic shortwave diathermy (SWD), 20 min/session, 3 sessions/week for 3 weeks
Number of subjects: 113
Study 18178111 — intervention group
Group type: COMPARATOR
Intervention: Sham shortwave diathermy (SWD)
Number of subjects: 113
Study 16448427 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 57
Study 16448427 — intervention group
Group type: EXPERIMENTAL
Intervention: PKRP
Number of subjects: 57
Study 12757534 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus
Number of subjects: 40
Study 12757534 — intervention group
Group type: COMPARATOR
Intervention: Spectra
Number of subjects: 40
Study 12757534 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus and Spectra
Number of subjects: 40
Study 11509470 — intervention group
Group type: EXPERIMENTAL
Intervention: 256-mg ferrous sulfate daily for 4 weeks
Number of subjects: 19
Study 11509470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9354196 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 10 mg
Number of subjects: 24
Study 9354196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 24
Study 9354196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7958150 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of fluconazole
Number of subjects: 0
Study 7958150 — intervention group
Group type: COMPARATOR
Intervention: Single intravaginal dose of 500 mg clotrimazole
Number of subjects: 0
Study 2443762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 34
Study 2443762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 34
Study 31591045 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Sanyinjiao for 8 weeks (experimental group)
Number of subjects: 53
Study 31591045 — intervention group
Group type: COMPARATOR
Intervention: Sham group without acupressure (control group)
Number of subjects: 53
Study 30457060 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist (GnRHa)
Number of subjects: 60
Study 28431559 — intervention group
Group type: EXPERIMENTAL
Intervention: RFB/RKB + RS
Number of subjects: 21
Study 28431559 — intervention group
Group type: EXPERIMENTAL
Intervention: RFB
Number of subjects: 21
Study 28431559 — intervention group
Group type: EXPERIMENTAL
Intervention: RFB/RKB
Number of subjects: 21
Study 28431559 — intervention group
Group type: COMPARATOR
Intervention: WWB
Number of subjects: 21
Study 25534065 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention based on Teaching Recovery Techniques (TRT)
Number of subjects: 482
Study 25534065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 482
Study 23269410 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 9
Study 23269410 — intervention group
Group type: COMPARATOR
Intervention: No Exercise (NE)
Number of subjects: 9
Study 21251991 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate
Number of subjects: 30
Study 21251991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18296964 — intervention group
Group type: EXPERIMENTAL
Intervention: Low velocity resistance training (LV)
Number of subjects: 34
Study 18296964 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 34
Study 18296964 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional strength (TS)
Number of subjects: 34
Study 18296964 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional endurance (TE)
Number of subjects: 34
Study 16253975 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily) for 6 months
Number of subjects: 37
Study 16253975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37
Study 12693807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol
Number of subjects: 42
Study 12693807 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin, ethambutol and isoniazid
Number of subjects: 42
Study 10991886 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (1,800 mg) with high-lipid diet
Number of subjects: 0
Study 10991886 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (1,800 mg) with high-carbohydrate diet
Number of subjects: 0
Study 8667160 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed-thinking tasks to manipulate the salience of desirable self-characteristics
Number of subjects: 0
Study 8667160 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed-thinking tasks to manipulate the salience of undesirable self-characteristics
Number of subjects: 0
Study 1587429 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b
Number of subjects: 115
Study 1587429 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 1587429 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa‐2b with prednisone priming
Number of subjects: 115
Study 3898905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide 50 micrograms per nostril b.i.d.
Number of subjects: 99
Study 3898905 — intervention group
Group type: COMPARATOR
Intervention: Oral flunisolide 500 micrograms b.i.d.
Number of subjects: 99
Study 3898905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intranasal and oral) b.i.d.
Number of subjects: 99
Study 31276193 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fluid restriction
Number of subjects: 1554
Study 31276193 — intervention group
Group type: COMPARATOR
Intervention: Standard care (IV fluid therapy)
Number of subjects: 1554
Study 29696659 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent factor mixed models (LFMMs)
Number of subjects: 202
Study 29696659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moran spectral outlier detection/randomization (MSOD‐MSR)
Number of subjects: 202
Study 29696659 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate SNPs identified through LFMMs and MSOD‐MSR
Number of subjects: 202
Study 29696659 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes tagged by candidate loci associated with drought and salinity
Number of subjects: 202
Study 29696659 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes tagged by candidates associated with soil nitrogen and atmospheric nitrogen
Number of subjects: 202
Study 26562755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐week endurance exercise program (three cycle ergometer sessions per week)
Number of subjects: 33
Study 25125506 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (40 mg b.i.d.)
Number of subjects: 76
Study 25125506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23299270 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheets applied to half of the scar for 6 months
Number of subjects: 10
Study 23299270 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheets
Number of subjects: 10
Study 23299270 — intervention group
Group type: COMPARATOR
Intervention: Untreated scar sides
Number of subjects: 10
Study 20708858 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition (believing they ingested 500 mg of disulfiram)
Number of subjects: 0
Study 20708858 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition (believing they ingested a placebo)
Number of subjects: 0
Study 18374395 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanner (temporary prostatic stent)
Number of subjects: 186
Study 16208302 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion sessions (10 sessions, twice a week for 5 weeks)
Number of subjects: 31
Study 16208302 — intervention group
Group type: COMPARATOR
Intervention: AcupunctureSham (10 sessions, twice a week for 5 weeks)
Number of subjects: 31
Study 16208302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 12654073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory integrative therapy (n=15)
Number of subjects: 45
Study 12654073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation in addition to sensory integrative therapy (n=15)
Number of subjects: 45
Study 12654073 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy (n=15)
Number of subjects: 45
Study 10477025 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based patient positioning system
Number of subjects: 11
Study 10477025 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment room lasers
Number of subjects: 11
Study 8735995 — intervention group
Group type: EXPERIMENTAL
Intervention: High contextual interference (serial condition)
Number of subjects: 24
Study 8735995 — intervention group
Group type: COMPARATOR
Intervention: Low contextual interference (blocked condition)
Number of subjects: 24
Study 8394538 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza) and Prednisolone (P), n = 54
Number of subjects: 195
Study 8394538 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (CsA) and Prednisolone (P), n = 58
Number of subjects: 195
Study 8394538 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy of Aza-CsA-P, n = 41
Number of subjects: 195
Study 8394538 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy of Aza-P, n = 42
Number of subjects: 195
Study 8394538 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunotherapy
Number of subjects: 195
Study 3013772 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (40 mmol per day)
Number of subjects: 10
Study 3013772 — intervention group
Group type: COMPARATOR
Intervention: High-sodium diet (300 mmol per day)
Number of subjects: 10
Study 29378416 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 131
Study 29378416 — intervention group
Group type: COMPARATOR
Intervention: Online training
Number of subjects: 131
Study 27196093 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine multilevel intervention (MLI)
Number of subjects: 337
Study 27196093 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine multilevel intervention (comparison group)
Number of subjects: 337
Study 23625461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthened position (LL, 40‐90° knee flexion)
Number of subjects: 31
Study 23625461 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened position (SL, 0‐50° knee flexion)
Number of subjects: 31
Study 23625461 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 31
Study 23625461 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining effects in SL
Number of subjects: 31
Study 22948897 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 0
Study 22948897 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide 350 mg/day
Number of subjects: 0
Study 22948897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22948897 — intervention group
Group type: COMPARATOR
Intervention: Selegiline 10 mg/day
Number of subjects: 0
Study 22948897 — intervention group
Group type: COMPARATOR
Intervention: Phenelzine 30 mg/day
Number of subjects: 0
Study 20004013 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU oxytocin (n=292)
Number of subjects: 577
Study 20004013 — intervention group
Group type: COMPARATOR
Intervention: 5 mL water (placebo) (n=285)
Number of subjects: 577
Study 18203329 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 22
Study 18203329 — intervention group
Group type: COMPARATOR
Intervention: Control (DMARD therapy)
Number of subjects: 22
Study 16848175 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine mesilate and Flunarizine Hydrochloride
Number of subjects: 60
Study 16848175 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 and Flunarizine Hydrochloride
Number of subjects: 60
Study 14602541 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (10 weeks)
Number of subjects: 58
Study 10448261 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg
Number of subjects: 46
Study 10448261 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg
Number of subjects: 46
Study 7919590 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 4500
Study 7919590 — intervention group
Group type: COMPARATOR
Intervention: No calcium blocker
Number of subjects: 4500
Study 2689018 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine cream 0.5%
Number of subjects: 40
Study 2689018 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole cream 1%
Number of subjects: 40
Study 788464 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting amitriptyline (Diffucaps) 25 mg at evening meal
Number of subjects: 0
Study 788464 — intervention group
Group type: COMPARATOR
Intervention: Ordinary amitriptyline 40 mg at bedtime
Number of subjects: 0
Study 31557067 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete lymph node dissection (CLND)
Number of subjects: 483
Study 31557067 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 483
Study 28556506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 5 mg
Number of subjects: 323
Study 28556506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 10 mg
Number of subjects: 323
Study 28556506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 15 mg
Number of subjects: 323
Study 28556506 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 5 mg
Number of subjects: 323
Study 28556506 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 10 mg
Number of subjects: 323
Study 25460344 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-mediated program combining problem solving training (PST) with modules for depression, anxiety, insomnia, and headache.
Number of subjects: 0
Study 23870174 — intervention group
Group type: EXPERIMENTAL
Intervention: Argan oil (25 mL/day for 3 weeks)
Number of subjects: 39
Study 23870174 — intervention group
Group type: COMPARATOR
Intervention: Butter (control group)
Number of subjects: 39
Study 21585288 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg p.o. (positive control)
Number of subjects: 80
Study 21585288 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg/day p.o. for 14 days
Number of subjects: 80
Study 21585288 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 1000 μg/day p.o. for 14 days
Number of subjects: 80
Study 18263674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 19
Study 18263674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16816559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral adherence intervention
Number of subjects: 230
Study 16816559 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 230
Study 12735570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma
Number of subjects: 56
Study 12735570 — intervention group
Group type: COMPARATOR
Intervention: Albumin 5%
Number of subjects: 56
Study 11068941 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 40
Study 11068941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9313729 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm axial spiral CT protocol
Number of subjects: 35
Study 9313729 — intervention group
Group type: COMPARATOR
Intervention: 10 mm axial spiral CT protocol
Number of subjects: 35
Study 7953259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg per rectum
Number of subjects: 60
Study 7953259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg intravenously
Number of subjects: 60
Study 7953259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine with intravenous benzodiazepines
Number of subjects: 60
Study 7953259 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac or pethidine alone
Number of subjects: 60
Study 2441163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine alone, 250 mg intravenously (i.v.)
Number of subjects: 10
Study 2441163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine alone, increasing dose of 0.04‐0.16 mg/kg/min
Number of subjects: 10
Study 2441163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion after caffeine
Number of subjects: 10
Study 31404005 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid minimally invasive esophagectomy (HMIE)
Number of subjects: 0
Study 31404005 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 0
Study 30151409 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose every 6 months)
Number of subjects: 0
Study 30151409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose every 6 months)
Number of subjects: 0
Study 28216062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (18 mg)
Number of subjects: 22
Study 28216062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 26242149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine treatment (anastrozole, exemestane)
Number of subjects: 0
Study 26242149 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (doxorubicin plus paclitaxel)
Number of subjects: 0
Study 26242149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with trastuzumab
Number of subjects: 0
Study 23108194 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 60 days
Number of subjects: 69
Study 23108194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 20530282 — intervention group
Group type: EXPERIMENTAL
Intervention: IROX (irinotecan + oxaliplatin)
Number of subjects: 520
Study 20530282 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (fluorouracil + oxaliplatin)
Number of subjects: 520
Study 20530282 — intervention group
Group type: EXPERIMENTAL
Intervention: IFL (fluorouracil + irinotecan)
Number of subjects: 520
Study 18222261 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation (group I, n = 39)
Number of subjects: 80
Study 18222261 — intervention group
Group type: COMPARATOR
Intervention: Unprotected controls (group II, n = 41)
Number of subjects: 80
Study 18222261 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation (group I)
Number of subjects: 80
Study 18222261 — intervention group
Group type: COMPARATOR
Intervention: Unprotected controls (group II)
Number of subjects: 80
Study 16857131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin flap LASIK
Number of subjects: 42
Study 16857131 — intervention group
Group type: COMPARATOR
Intervention: LASEK
Number of subjects: 42
Study 14664876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 64
Study 14664876 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 64
Study 14664876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 10809397 — intervention group
Group type: EXPERIMENTAL
Intervention: Remineralizing solution only (Group A)
Number of subjects: 0
Study 10809397 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid etching for 30 s + remineralizing solution (Group B)
Number of subjects: 0
Study 10809397 — intervention group
Group type: EXPERIMENTAL
Intervention: Remineralizing solution + daily fluoride toothpaste slurry (1,000 ppm for 5 min) (Group C)
Number of subjects: 0
Study 10809397 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid etching + daily fluoride treatment (Group D)
Number of subjects: 0
Study 14688950 — intervention group
Group type: EXPERIMENTAL
Intervention: Special preterm formula
Number of subjects: 70
Study 14688950 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified formula
Number of subjects: 70
Study 14688950 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 70
Study 1354432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.1 g
Number of subjects: 10
Study 1354432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.2 g
Number of subjects: 10
Study 1354432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.2 g with Maalox 70 (10 ml 2h and 10 ml 15 min before)
Number of subjects: 10
Study 1354432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 0.2 g with famotidine (40 mg 1h before)
Number of subjects: 10
Study 6896649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.2 mg kg‐1 in 10% dextrose solution)
Number of subjects: 18
Study 6896649 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine (0.2 mg kg‐1 in 0.9% saline)
Number of subjects: 18
Study 6896649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine (0.2 mg kg‐1 in 0.9% saline)
Number of subjects: 18
Study 6896649 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 31194778 — intervention group
Group type: COMPARATOR
Intervention: Oral treatments (risperidone, olanzapine)
Number of subjects: 12232
Study 31194778 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectables (risperidone long acting, paliperidone long acting)
Number of subjects: 12232
Study 31194778 — intervention group
Group type: COMPARATOR
Intervention: Oral treatments (clozapine, olanzapine)
Number of subjects: 12232
Study 31194778 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectables
Number of subjects: 12232
Study 31194778 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting treatment switched from another long-acting
Number of subjects: 12232
Study 29701875 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal surrogate based on super-learner and targeted super-learner estimators
Number of subjects: 0